Sun Pharma Advanced Research Co Quarterly Results for Trading Insights
In Mar 2026, Sun Pharma Advanced Research Co (SPARC) reported revenue ₹15 Cr and net profit ₹1,761 Cr — revenue -44.4% YoY. View SPARC 52-week high low for the annual high/low range and current price position.
SPARC Quarterly Results — Revenue, Profit & EPS Highlights
Sun Pharma Advanced Research Co latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Sun Pharma Advanced Research C ownership structure to track promoter, FII and institutional holdings.
- Revenue of ₹15 Cr in Mar 2026 (-76.6% vs Jun 2026, -44.4% vs Mar 2025)
- Net Profit of ₹1,761 Cr in Mar 2026 (+8485.7% vs Jun 2026, +3035.0% vs Mar 2025)
- EBITDA of ₹-65 Cr in Mar 2026 (-550.0% vs Jun 2026)
- Operating Margin of -506.0% in Mar 2026 (-421.0pp vs Jun 2026)
- Earnings Per Share of ₹54.27 in Mar 2026 (+8579.7% vs Jun 2026)
Sun Pharma Advanced Research Co Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SPARC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 15 | 64 | 8 | 27 | 19 | -76.6% | -44.4% |
| Net Profit (₹ Cr) | 1,761 | -21 | -76 | -60 | -52 | - | - |
| EBITDA (₹ Cr) | -65 | -10 | -66 | -53 | -43 | - | - |
| EPS (₹) | 54.27 | -0.64 | -2.34 | -1.84 | -1.60 | - | - |
| Operating Margin (%) | -506.0% | -85.0% | -836.0% | -196.0% | -540.0% | - | - |
SPARC Share Price Trend — 1-Year Movement Across Quarterly Results
Sun Pharma Advanced Research Co 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SPARC screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SPARC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sun Pharma Advanced Research Co latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores